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The Economic Burden of Dengue
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University of Singapore Graduate Medical School, Singapore
Historically, dengue has been considered an unimportant
public health problem because mortality rates were low and
epidemics occurred only infrequently. In the years after World
War II, great progress was made in controlling infectious dis-
eases of all kinds, especially vector-borne diseases, and the war
on infectious disease was declared won in the late 1960s.
1 Coin-
cident with this success in disease control was the economic
recovery in some countries of Southeast Asia, and urban
growth increased as people from rural areas migrated to the
cities to find work. The lack of planning, inadequate housing,
water, sewage, and waste management in these cities created
ideal conditions for dengue viruses and their mosquito vector
Aedes aegypti,b o t ho fw h i c hh a db e e ns p r e a dw i d e l yi nt h e
region during World War II, to thrive.
2 The result was the emer-
gence of epidemic dengue hemorrhagic fever. During the
1950s and 1960s, the disease was limited to a few countries in
Southeast Asia, but as economic growth expanded, the cities
and epidemic dengue also grew, because little effort was made
to control the mosquito vector. In the 1970s and accelerating
in the last two decades of the 20th century, epidemic dengue
expanded regionally and globally. Epidemics increased in
both frequency and magnitude, and the viruses became hyper-
endemic (cocirculation of multiple virus serotypes) in most
major cities of the tropics. Despite this alarming emergence
of a severe and fatal form of epidemic dengue, the disease was
still considered a minor public health problem by policymakers.
In 2012, dengue is the most important vector-borne viral
disease of humans and likely more important than malaria
globally in terms of morbidity and economic impact. The
latest studies estimate 3.6 billion people living in areas of risk,
over 230 million infections, millions of cases of dengue fever,
over 2 million cases of the severe disease, and 21,000 deaths.
3
In addition to the public health and economic costs, there is a
major social impact in those countries where large epidemics
occur, often disrupting primary care for hospitalized patients.
4
Given the dramatic urban growth and lack of adequate sur-
veillance for dengue in tropical developing countries in the
past 50 years, it is likely that even these figures underestimate
the true disease burden of dengue.
Thus, ignored for many years, only recently has the potential
magnitude of the dengue problem been acknowledged by
policymakers and funding agencies. This acknowledgment has
resulted in excellent progress in understanding dengue virus
biology and development of dengue vaccines and antiviral
drugs but not economic impact of the disease. As the pipeline
of dengue vaccine candidates, a number of which are already in
clinical trials, has grown, it has become apparent that vaccine
access will require more and better studies on the actual cost of
dengue to endemic communities. In recent years, many studies
have been conducted in different Asian and American coun-
tries in attempts to measure the economic impact of dengue on
a community. Although most have contributed valuable infor-
mation on the subject, none has provided comprehensive data
on the actual cost of dengue disease. The work by Halasa and
others
5 provides one of the best studies to date on that subject.
Working in collaboration with the Puerto Rico Department
of Health and the US Centers for Disease Control and Pre-
vention Dengue Branch in Puerto Rico, the investigators con-
ducted a comprehensive review of 100 laboratory-confirmed
dengue patients who experienced the disease between July
of 2008 and March of 2010. The study included both adults
and children and hospitalized and ambulatory care patients.
Records were reviewed for each patient, who was then sub-
jected to a comprehensive interview about their illness and
how it impacted their activities. The work by Halasa and
others
5 measured the cost, both direct and indirect, of dengue
in six categories of cases and went to considerable effort to
validate their data. The results, perhaps not surprisingly, show
the economic burden of dengue in Puerto Rico to be very
high. This study is the first study to show the societal distri-
bution of the economic cost of dengue, with the individual
household bearing the largest burden (48%) compared with
only 24% by the government and 22% by insurance.
5 The
total annual cost of dengue between 2002 and 2010 was
$46.45 million ($418 million during the 9-year period).
5
Clearly, there is a need to conduct more comprehensive
studies of this kind in other dengue-endemic countries of the
world. These kinds of data are needed to allow policymakers
and public health officials to make informed decisions on the
cost efficacy of dengue control programs. The private sector
also needs comprehensive economic analyses to guide decision-
making in vaccines and antiviral drug development. Finally,
international funding agencies require these kinds of data to
establish priorities in public health funding.
Studies of this kind will always have limitations, and this
study was no exception. However, the work by Halasa and
others
5 clearly identified the most important limitations, such
as recall bias and not being able to estimate the cost of tourism
and deaths associated with dengue. The latter two limitations,
however, would add to the overall cost of dengue, driving the
cost even higher. The fact that the study was supported by a
private vaccine manufacturer might raise questions about con-
flict of interest by some people. In my mind, however, this
possibility is not an issue because of the detailed methodology
used and the reputation of the Brandeis group as the leader
in research on the economic impact of dengue.
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